Approved

Corticotropin: Uses, Mechanism, and Reported Side Effects

Molecular formulaC207H308N56O58S
Molecular weight4541 g/mol
Registered trials517
PubChem CID16132265
Drug classAdrenocorticotropic Hormone [EPC]
Brand namesGUNA-GERIATRICS

Anyone researching corticotropin usually wants to know what it actually does in the body and what problems patients have reported while using it. This overview summarizes the available label, trial, and safety report data in plain terms.

Key takeaways

  • Corticotropin is classified as an adrenocorticotropic hormone, with additional oxytocic and thyroid stimulating hormone activity labels.
  • It is identified in PubChem under CID 16132265 and has the molecular formula C207H308N56O58S.
  • More than 500 clinical trials reference corticotropin or related compounds in the registry.
  • The most frequently reported issues in safety reports are fatigue and injection site reactions.
  • No boxed warning is present on the label reviewed.

What Corticotropin Is

Corticotropin belongs to a class of hormone-based agents labeled as adrenocorticotropic, oxytocic, and thyroid stimulating hormone drugs. These classifications point to broad hormonal activity affecting the adrenal, uterine, and thyroid systems. A specific mechanism of action description was not available in the label data reviewed.

What The Evidence Shows

The clinical trial registry lists 517 trials associated with corticotropin. Sample entries include a completed study on urocortins and forearm arterial blood flow in healthy volunteers, and a completed trial characterizing metabolic and brain effects of rising glucagon during an oral glucose challenge. These examples illustrate the range of research contexts in which the compound or related hormones have been studied, though not every listed trial focuses specifically on corticotropin itself.

Reported Side Effects

Safety reports submitted to FAERS most commonly describe general and injection-related effects. Fatigue was the most reported term (249 reports), followed by injection site bruising (208) and injection site pain (171). Headache (164), issues with missed doses (160), and insomnia (151) were also frequently reported. Reports of the drug being ineffective (128) and weight increase (120) round out the most common terms. These figures represent counts of submitted reports, not confirmed incidence rates or evidence of causation.

FAQ

What type of drug is corticotropin?
Corticotropin is labeled as an adrenocorticotropic hormone, with additional classifications as an oxytocic agent and a thyroid stimulating hormone. This reflects its broad hormonal activity across multiple body systems rather than a single narrow function.
What are the most commonly reported side effects of corticotropin?
The most frequently reported issues in safety databases include fatigue, injection site bruising, and injection site pain. Headache, insomnia, and weight increase have also been reported. These are counts of submitted reports, not confirmed rates of occurrence.
How many clinical trials have studied corticotropin or related compounds?
The clinical trials registry lists 517 trials connected to corticotropin. Sample studies include research on related hormones such as urocortins and glucagon in different physiological contexts.
Does corticotropin carry a boxed warning?
No, the label data reviewed for corticotropin does not include a boxed warning.
Is drug ineffectiveness a commonly reported issue with corticotropin?
Yes, reports describing the drug as ineffective were among the more frequently logged terms in safety databases, with 128 reports. This reflects patient or provider reporting, not a confirmed measure of treatment failure.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: FDA label data (DailyMed) PubChem CID 16132265 ClinicalTrials.gov registry FDA Adverse Event Reporting System (FAERS)

Updated 2026-09-19